Get the app
US › Healthcare

Spruce Biosciences, Inc. Common Stock (SPRB)

US · Healthcare · Biotechnology

$39.65-4.39%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-16.2M
EPS
$-6.68
EPS estimate
$-4.79

EPS came in at -6.68 against a street estimate of -4.79 — a miss of 39.5%.

Key statistics

Market cap
$116.0M
Forward P/E
0.0
P/B
1.70
Book value
$30.42
EPS (TTM)
$-39.12
52-week high
$163.00
52-week low
$38.06
50-day MA
$51.54
200-day MA
$58.47
Beta
3.30

Analyst view

Analysts rate Spruce Biosciences, Inc. Common Stock a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $148.00.

Shareholding

Insiders
3.37%
Institutions
76.88%

Largest institutional holders

FundStake
AIGH Capital Management, LLC8.70%
Orbimed Advisors LLC6.96%
BlackRock Inc6.54%
Millennium Management LLC5.60%
Ikarian Capital, LLC4.22%
Vanguard Capital Management, LLC4.15%
Alyeska Investment Group, L.P.2.84%
Geode Capital Management, LLC2.45%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Spruce Biosciences, Inc. Common Stock — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.